from DHHS should be directed to Andrew J. Hagan, OCSE (telephone (202) 401–5375). This is not a toll-free number. Any written comments on the minutes should be directed to Ms. Samara Weinstein, Executive Director of the Working Group, as shown above.

Signed at Washington, DC, this 29th day of March, 1999.

David Gray Ross,

Commissioner, Office of Child Support Enforcement.

[FR Doc. 99–8317 Filed 4–2–99; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N–0038]

Agency Information Collection Activities; Announcement of OMB Approval; Survey of Biomedical Equipment Manufacturers for Year 2000–Compliant Products

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Survey of Biomedical Equipment Manufacturers for Year 2000–Compliant Products'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of January 22, 1999 (64 FR 3524), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0397. The approval expires on September 30, 1999. A copy of the supporting statement for this information collection is available on the Internet at ''http://www.fda.gov/ohrms/dockets''.

Dated: March 29, 1999.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 99–8201 Filed 4–2–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Public Input on Public Health; Open Public Forum

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meetings.

SUMMARY: The Food and Drug Administration (FDA), Office of Consumer Affairs and Office of Regulatory Affairs, Pacific Region, is announcing a series of open public forums entitled: ''Public Input on Public Health, FDA Listens to You, A Town Hall Meeting.'' The purpose of the forums is to provide an opportunity for FDA's primary stakeholders, U.S. consumers, to have an open dialogue with FDA's senior policy makers about their consumer protection concerns. FDA plans to use the information in the development of the Pacific Region Strategic Plan and in the development of FDA's nation wide priorities. Under the FDA Modernization Act of 1997 (FDAMA), FDA was mandated by Congress to have ongoing consultations with its stakeholders on how FDA can best meet their regulatory requirements and to protect the public health. Two issues of particular concern, this year, are strengthening the science base of the agency and improving risk-based communication with the public.

DATES: Send registration and requests for oral presentations by May 5, 1999. See Table 1 in section II of this document for a complete schedule of all the meetings.

ADDRESSES: Send written comments to the specific contact person. See Table 1 in section II of this document for a complete listing of meeting locations and contact persons.

FOR FURTHER INFORMATION CONTACT:

For general information: James Rowell or Patricia Alexander, Food and Drug Administration, 5600 Fishers Lane, rm. 16–75, Rockville, MD 20857, 301–827–4414 or 301–827–4391, FAX 301–443–9767.

For specific meeting information: See Table 1 in the **SUPPLEMENTARY INFORMATION** section of this document.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is a science based consumer protection agency responsible for ensuring that: (1) Foods are safe, wholesome and sanitary; (2) human and veterinary drugs, biological products, and medical devices are safe and effective; (3) cosmetics and electronic products that emit radiation are safe. FDA also ensures that these regulated products are honestly and accurately labeled and in compliance with applicable laws and regulations. FDA strives to maximize public health protection while reducing regulatory burdens.

Public participation in these forums will provide an essential ingredient to the achievement of the Pacific Region's intermediate and long range strategic planning goals. Additional benefits include: (1) Providing the opportunity to hear directly from consumers their concerns about health and policy issues, (2) reaching out to a broad representation of community based and consumer organizations to reach the full diversity of consumers, (3) using the information gained at these forums in FDA's decisionmaking process, (4) obtaining information necessary for the development of innovative programs to raise public awareness, (5) fostering communication among local agencies, both public and private, in order to more effectively respond to the public's need for information that empowers them in making health related decisions, and (6) encouraging individuals to take personal responsibility for protecting their own health.

II. Scheduled Meetings

The open public forums will be held in several locations throughout the country. The scheduled date and time, location, and specific contact person for each meeting is listed in Table 1 as follows:

TABLE 1.—MEETING SCHEDULES AND CONTACTS FOR REGISTRATION

Date	Time	Place	Address	Contact
Wednesday, May 12, 1999	10 a.m. to 1 p.m.	Elihu Harris State Office Bldg. Auditorium.	1515 Clay St., Oakland, CA.	Mary Ellen Taylor at 510–337–6888, FAX 510–337–6708

TABLE 1.—MEETING SCHEDULES AND CONTACTS FOR REGISTRATION—Continued

Date	Time	Place	Address	Contact
	4 p.m. to 7 p.m.	Elihu Harris State Office Bldg. Auditorium.	1515 Clay St., Oakland, CA.	Mary Ellen Taylor at 510–337–6888, FAX 510–337–6708
Friday, May 14, 1999	10 a.m. to 3 p.m.	California Science Center, Donald P. Loker Conference Center.	Figueroa and 39th Sts., Los Angeles, CA, (next to the Los Angeles Coliseum).	Rosario Vior at 949–798–7607, FAX 949–798–7715
Monday, May 17, 1999	1 p.m. to 4 p.m.	Portland State University, Smith Memorial Center.	724 SW. Harrison St., rm. 294, Portland, OR.	Alan Bennett at 503–671–9711, ext. 22 FAX 503–671–9711

III. Registration and Requests for Oral Presentations

Send registration information (including name, title, firm name, address, telephone, and fax number) and requests to make oral presentations to the registration contact person listed in Table 1 of section II of this document by Wednesday, May 5, 1999.

Written comments and questions concerning the meetings may also be submitted to the specific registration contact person listed for each meeting in Table 1. If you need special accommodations due to a disability, please contact the registration contact person at least 7 days in advance.

IV. Transcripts

Transcripts of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page.

Dated: March 29, 1999.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 99–8200 Filed 4–2–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Extramural Support Program for Projects to Increase Organ and Tissue Donation

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice with comment period.

SUMMARY: The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS), announces a proposed peer reviewed, competitively awarded extramural support program for fiscal year 1999 to fund projects to increase organ and tissue donation. This document sets forth the proposed parameters of the extramural support program and offers a 30-day period for public comment on: the project phases eligible for program support (pilot tests and replications), performance measures, funding priorities, and review criteria. Comments will be considered for the purpose of writing the detailed guidance to applicants for submission of applications. Applications will be solicited for this extramural support program by posting the announcement on the following three web sites: www.hrsa.gov, www.hrsa.gov/osp/dot/, and www.organdonor.gov, and by publishing it as a **Federal Register** notice.

In concert with HHS'' National Organ and Tissue Donation Initiative, this extramural program intends, through cooperative agreements, to support projects of up to 3 years duration to implement, evaluate, and disseminate model interventions with the greatest potential for yielding a verifiable and demonstrable impact on donation and which are replicable, transferable, and feasible in practice. Applicants must be qualified organ procurement organizations (OPOs) or other nonprofit, private organizations, in collaboration with a consortium of other relevant entities. Strong evaluation project components and staffing expertise are required. Authority for this program is provided by Section 371(a)(3) of the Public Health Service (PHS) Act, 42 U.S.C. 273(a)(3), as amended.

DATES: To ensure consideration, comments must be received by May 5, 1999.

ADDRESSES: Written comments should be addressed to: D.W. Chen, M.D., M.P.H., Director, Division of Transplantation, Office of Special Programs, Health Resources and Services Administration, U.S. Department of Health and Human Services, Room 4–81, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. All comments received will be available for public inspection and copying at the Division of Transplantation, at the above address, weekdays (Federal holidays excepted) between the hours of 9:00 a.m. and 5:00 p.m.

FOR FURTHER INFORMATION CONTACT: D.W. Chen, M.D., M.P.H., Director, Division of Transplantation, Office of Special Programs, Health Resources and Services Administration, U.S. Department of Health and Human Services, Room 4–81, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857; 301 443–7577.

SUPPLEMENTARY INFORMATION:

Purposes

Organ donation has become an increasingly important public health issue. Only about 5,500 deaths in the United States each year result in organ donation, compared with an estimated potential of 8,000–15,000 donors. Moreover, almost 62,000 patients are currently awaiting transplants and about 4,000 patients die each year because of the critical shortage of transplantable organs.

A major barrier to donation today is low rates of family consent. The Health Care Financing Administration's revised Hospital Conditions of Participation for Organ, Tissue, and Eye Donation (June 22, 1998, 63 Fed. Reg. 33856) effective August 21, 1998, are designed to maximize opportunities to donate by requiring Medicaid-and Medicare-participating hospitals to notify OPOs of all deaths and imminent deaths so potential donors are identified and families are asked about donation; however, only about half of families who are asked give their consent. The latest national Gallup survey indicates that nearly all Americans would consent to donation if they knew that their loved one had requested it, but only about half of Americans who want to donate have told their families.

The goals of this program are to implement, evaluate, and disseminate